Verve Therapeutics Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201 in Wild-type and LDLR-deficient Non-Human Primates
VERVE-201 Preclinical Data Supports Advancement of Drug Candidate Toward Clinical Development for Homozygous Familial Hypercholesterolemia, with Initiation of Clinical Trial Anticipated in 2024 Data... | March 3, 2023
United States Jen Robinson Andrew Bellinger Exchange Commission Editing Medicine Targeting Clinical Development For Homozygous Familial Hypercholesterolemia
Source: marketscreener.com